Table 1 The published CAR T clinical reports in China
From: Clinical development of CAR T cell therapy in China: 2020 update
PMID | Year | Title | Institute | Target |
|---|---|---|---|---|
25174587 | 2015 | Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia | The General Hospital of the People’s Liberation Army, Beijing | CD33 |
25444722 | 2014 | Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells | The General Hospital of the People’s Liberation Army, Beijing | CD20 |
26451310 | 2015 | Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia | The General Hospital of the People’s Liberation Army, Beijing | CD19 |
26961900 | 2016 | Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells | Soochow University, Suzhou | MUC1 |
26968708 | 2016 | Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer | The General Hospital of the People’s Liberation Army, Beijing | EGFR |
27526682 | 2016 | Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T-cell therapy | The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou | CD19 |
27582488 | 2017 | Autologous T cells-expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin’s lymphoma: an open-label phase I trial | The General Hospital of the People’s Liberation Army, Beijing | CD30 |
27887660 | 2016 | Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia | The General Hospital of the People’s Liberation Army, Beijing | CD19 with stem cells transplantation |
28039267 | 2017 | Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia | The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou | CD19 |
28057014 | 2017 | Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma | The General Hospital of the People’s Liberation Army, Beijing | EGFR and CD133 |
28366766 | 2017 | Phase I Escalating-Dose Trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers | Southwest Hospital, Third Military Medical University, Chongqing | CEA |
28577043 | 2017 | Anti-CD138 chimeric antigen receptor-modified T-cell therapy for multiple myeloma with extensive extramedullary involvement | Tianjin Medical University Cancer Institute and Hospital, Tianjin | CD138 |
28710747 | 2018 | Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers | The General Hospital of the People’s Liberation Army, Beijing | HER2 |
29138340 | 2017 | Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers | The General Hospital of the People’s Liberation Army, Beijing | EGFR |
29263894 | 2016 | Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report | The General Hospital of the People’s Liberation Army, Beijing | CD20 |
29458388 | 2018 | A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia | Guangdong General Hospital, Guangzhou | CD19 |
29503204 | 2018 | In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou | CD19 |
29637550 | 2018 | Treatment of acute lymphoblastic leukemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB | Southwest Hospital, Third Military Medical University, Chongqing | CD19 |
29900044 | 2018 | CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial | The General Hospital of the People’s Liberation Army, Beijing | CD133 |
30348186 | 2018 | Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma | Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan | BCMA |
30572922 | 2018 | A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T-cell therapy directed against B-cell maturation antigen, in patients with relapsed or refractory multiple myeloma | The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an | BCMA |
30988175 | 2019 | Exploratory trial of a biepitopic CAR T-targeting B-cell maturation antigen in relapsed/refractory multiple myeloma | Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai | BCMA |
31011207 | 2019 | A safe and potent anti-CD19 CAR T-cell therapy | Peking University Cancer Hospital and Institute, Beijing | CD19 |
31055613 | 2019 | Improving the safety of CAR-T-cell therapy by controlling CRS-related coagulopathy | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan | CD19 |
31110217 | 2019 | CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia | Beijing Boren Hospital, Beijing | CD22 |
31321805 | 2019 | Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan | CD19 |
31378662 | 2019 | A combination of humanized anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial | the Affiliated Hospital of Xuzhou Medical University, Xuzhou | CD19 and BCMA |
31489688 | 2019 | Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome | Zhujiang Hospital, Southern Medical University, Guangzhou | CD19 |
31651858 | 2019 | CD56-chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma: a 3.5-year follow-up case report | Beijing Children’s Hospital, Capital Medical University, Beijing | CD56 |
31697824 | 2020 | Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan | CD19 and CD22 |
31725148 | 2020 | Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL | Beijing Boren Hospital, Beijing | CD19 and CD22 |
32321169 | 2020 | Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells | Beijing Boren Hospital, Beijing | CD19 and CD20 or CD22 |
32371538 | 2020 | Chimeric Antigen Receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of Phase I Trials | Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai | GPC3 |
32527643 | 2020 | Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial | The General Hospital of the People’s Liberation Army, Beijing | EGFR |
32536980 | 2020 | Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL | The General Hospital of the People’s Liberation Army, Beijing | CD19 with stem cells transplantation |
32556247 | 2020 | Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma | The General Hospital of the People’s Liberation Army, Beijing | CD19 and CD20 |
